{"id":"pib-0-2-ropivacaine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (pain, erythema)"},{"rate":null,"effect":"Transient paresthesia"},{"rate":null,"effect":"Systemic toxicity (CNS effects, cardiac arrhythmias) with overdose"},{"rate":"rare","effect":"Allergic reactions"}]},"_chembl":{"chemblId":"CHEMBL1077896","moleculeType":"Small molecule","molecularWeight":"274.41"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ropivacaine reversibly inhibits sodium influx into nerve fibers, which stabilizes the neuronal membrane and prevents depolarization. This action blocks conduction of sensory, motor, and autonomic nerve impulses in the area where it is administered. The 0.2% concentration represents a dilute formulation suitable for infiltration anesthesia and regional anesthetic techniques.","oneSentence":"Ropivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:41:59.564Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Local infiltration anesthesia"},{"name":"Regional anesthesia and nerve blocks"},{"name":"Perioperative pain management"}]},"trialDetails":[{"nctId":"NCT04648774","phase":"NA","title":"Continuous Serratus Anterior Blockade for Sternotomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nova Scotia Health Authority","startDate":"2021-07-22","conditions":"Postoperative Pain, Opioid Use, Quality of Life","enrollment":50},{"nctId":"NCT03696095","phase":"PHASE4","title":"Local Anesthetic Automated Intermittent Administration vs. Continuous Infusion Via Femoral Nerve Block.","status":"COMPLETED","sponsor":"J P Lecoq","startDate":"2018-04-16","conditions":"Postoperative Pain, Postoperative Complications","enrollment":70},{"nctId":"NCT02707874","phase":"PHASE4","title":"PIB Versus CI Through a Popliteal Sciatic Nerve Catheter for Analgesia Following Major Ankle Surgery","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2014-10","conditions":"Pain, Postoperative","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ropivacaine 0.2% Programmed intermittent bolus"],"phase":"marketed","status":"active","brandName":"PIB 0.2% ropivacaine","genericName":"PIB 0.2% ropivacaine","companyName":"University Health Network, Toronto","companyId":"university-health-network-toronto","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ropivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials. Used for Local infiltration anesthesia, Regional anesthesia and nerve blocks, Perioperative pain management.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}